Copy to clipboard 
Ensemble Orthopedics announced the 100th implantation of the Ensemble CMC minimally invasive joint replacement for the treatment of carpometacarpal (CMC or thumb) osteoarthritis, coinciding with the one-year anniversary of market introduction.
The FDA-cleared Ensemble CMC was designed to expand treatment options for CMC osteoarthritis in a wider range of patients by replacing only the affected bearing surfaces of the carpal and metacarpal bones. The interpositional device is inserted through a small incision with minimal disruption to the joint capsule or stabilizing soft tissue structures of the thumb.
Ensemble CMC is manufactured from pyrocarbon, a low friction material with a proven history of durability and biocompatibility in orthopedic implants.
Ensemble plans to build a complete line of minimally invasive implants for the hand and wrist. The company also received approval for its Ensemble CMC Wrist Protheses in 4Q20, marking its first FDA 510(k) clearance. The uncemented, one-piece joint prosthesis was designed to fit in the space between the trapezium and first metacarpal for patients with early stage arthritis.
